CDK9 and B-cell chronic lymphocytic leukemia: Altogether, these findings validate CDK9 as a favorable therapeutic target in CLL and up-regulation of the CDK9-associated pathways, including Mcl-1 and RNA transcription machinery contributes to the resistance of flavopiridol.